1. Age ≥ 18 years
2. Primary adenocarcinoma of the breast confirmed by histology or cytology. ER and/or PR+
3. Locally advanced or metastatic disease not amenable to surgery or radiation with curative intent. Must not have rapidly progressive disease
4. Must have failed hormonal manipulation with tamoxifen. May have received treatment with an aromatase inhibitor as first line therapy for metastatic disease prior to treatment with tamoxifen, but no other hormonal manipulation upon failing tamoxifen
5. ECOG performance status 0 – 2
6. Patients must have normal bone marrow, liver and kidney function.

1. Must have verified first local and/or regional recurrence of invasive breast cancer following primary treatment with mastectomy or breast conserving treatment
2. Must have surgical resection of the recurrence with uninvolved (clear) margins or surgical resection with microscopically involved margins (RI)
3. Cannot have evidence of distant metastasis on standard staging examinations
4. Must have measurement of hormone receptors in the recurrent tumor 
5. Must be medically suitable for chemotherapy of 3 to 6 months duration

This is a study to determine whether a regimen of dose-dense doxorubicin and cyclophosphamide followed by dose-dense paclitaxel and gemcitabine will be superior to a regimen of docetaxel, doxorubicin, and cyclophosphamide as well as to a regimen of dose-dense doxorubicin and cyclophosphamide followed by dose-dense paclitaxel alone in improving disease-free survival in women with node positive breast cancer.  Patients will be randomly assigned to one of four regimens:  (1) doxorubicin/cyclophosphamide (AC2) given every two weeks with pegfilgrastim support followed by paclitaxel also given every two weeks with pegfilgrastim support (T2); (2) an alternative dose-schedule of doxorubicin/cyclophosphamide with cyclophosphamide given orally on a daily basis and doxorubicin given weekly with filgrastim support followed by T2;  (3) AC2 followed by paclitaxel administered weekly (T1); or (4) continuous AC+G regimen followed by T1

1. The interval between last surgery for breast cancer staging or treatment and randomized must be not more than 84 days.
2. Patient’s tumor must be invasive carcinoma of the breast on histological examination.
3. Patients must have had either a lumpectomy or a total mastectomy.
4. Patients must complete one of the following procedures for evaluation of pathologic nodal status:  sentinel lymphadenectomy followed by removal of additional non-sentinel lymph node; sentinel lymphadenectomy according to criteria; or an axial lymphadenectomy.
5. Patients must have no clinical or radiologic evidence of metastatic disease.
6. Patients must be female with a life expectancy of at last 10 years and a Zubrod performance status of 0 or 1.

This research study is being conducted for postmenopausal women who have developed breast cancer. The purpose of this study is to find new ways to predict who will respond well to Letrozole therapy and to examine a patient’s breast cancer and blood to find out more about how Letrozole works. The research will also find out what effects taking the drug for 4 to 6 months before surgery will have on breast cancer. 

1. Have cancer of the breast that can be confirmed by a core-needle biopsy and that meets certain other clinical criteria
2. Have estrogen positive and/or progesterone positive tumors
3. Benefit from preoperative therapy with an improvement in surgical outcomes defined as: 
   Marginal candidate for lumpectomy (lumpectomy feasible but patient at risk for positive margins or poor cosmetic outcome). Patient desires breast-conserving surgery if possible 
   Ineligible for lumpectomy but modified radical mastectomy currently feasible. Patient desires breast-conserving surgery if possible and surgeon judges this would be possible if the primary tumor were smaller;
   Inoperable, systemic therapy required for patient to become operable by modified radical mastectomy.
4. Be postmenopausal
   Be willing to undergo breast surgery at the end of the preoperative treatment period.

This research study is being conducted for premenopausal women with early-stage hormone-receptor negative breast cancer. It will compare the rate of premature ovarian failure following standard adjuvant (assisting in the cure of disease) chemotherapy with or without the addition of ovarian suppression with a drug called a LHRH analog (luteinizing hormone-releasing hormone) during chemotherapy. Also, it will compare the rates of ovarian dysfunction following this treatment and evaluate ovarian reserves. The study will also describe pregnancy and fertility in the two groups after treatment and during the five-year follow-up period.

1.  Have a histologically confirmed diagnosis of operable Stage I, II, or IIA invasive breast cancer. Patients who have completed surgery must have pathologic Stage I, II, or IIA disease 
2. Be premenopausal 
3. Have tumors that are both estrogen receptor negative and progesterone receptor negative 
4. Be 18 years of age or greater and under age 50
5. Accept that planned treatment may include 3 to 8 months of cycles of an alkylating agent containing post-operative or pre-operative chemotherapy regimen, that chemotherapy will be administered in the pre-operative setting but not in the post-operative setting, and must be registered within 84 days after the final surgical procedure required to treat the primary tumor or axilla; 
6. Performance status 0-2;
7. Be able to give written informed consent.

This study is being conducted to evaluate whether partial breast irradiation (PBI) is as effective as whole breast irradiation (WBI) in keeping cancer from coming back to the breast following lumpectomy for early stage breast cancer. A random selection process will determine whether patients will be placed into Group 1 to receive WBI, or Group 2 to receive PBI. Patients in both groups may receive chemotherapy and hormonal therapy if their doctors decide it is necessary. 
Patients in Group 1 will start WBI soon after joining the study if there is no need for chemotherapy. If chemotherapy is needed, it will be given before radiation. After the chemotherapy is finished, WBI will be given once a day for 5 days a week over 5 to 7 weeks. Patients in Group 2 will start PBI soon after joining the study. The treatments will be given 2 times a day, about 6 hours apart, for 5 days. The treatments may be given over a period of 5 to 10 days. If chemotherapy is needed, it will start after the PBI treatment is finished. Both Group 1 and 2 will receive at least 5 years of hormonal therapy if an individual patient’s breast cancer is affected by hormones (estrogen or progesterone). If chemotherapy is needed, the hormonal therapy will begin after chemotherapy has ended. If chemotherapy is not needed, hormonal therapy can begin before, during, or after the radiation therapy. 

1. Stage 0 (DCIS) or stage I or II invasive adenocarcinoma of the breast with no evidence of metastatic disease. If stage II, tumor size must be 3 cm or less
2. Undergone a lumpectomy with the margins of the resected specimen histologically-free of cancer including DCIS
3. Axillary staging which can include sentinel node biopsy alone (if sentinel node is negative), sentinel node biopsy followed by axillary dissection or sampling with a minimum total of 6 axillary nodes (for invasive cancer)
4. Axillary nodes restricted to those with 0 to 3 positive axillary nodes
5. Life expectancy of at least ten years, excluding diagnosis of breast cancer 

This is a study to compare disease-free survival of patients with node-positive or high-risk node-negative breast cancer treated with the combination of doxorubicin and cyclophosphamide with pegfilgrastim support with that of patients treated weekly with doxorubicin and daily oral cyclophosphamide with filgrastim support with both treatments to be followed by paclitaxel given according to one of two schedules.  Patients will be randomly assigned to one of four treatment arms:  (1) doxorubicin/cyclophosphamide (AC2) given every two weeks with pegfilgrastim support followed by paclitaxel also given every two weeks with pegfilgrastim support (T2); (2) an alternative dose-schedule of doxorubicin/cyclophosphamide with cyclophosphamide given orally on a daily basis and doxorubicin given weekly with filgrastim support followed by T2; (3) AC2 followed by paclitaxel administered weekly (T1); or (4) continuous AC+G regimen followed by T1.

1. Patients must have had either a modified radical mastectomy or local excision of all tumors plus an axillary lymph node dissection or sentinel node resection prior to registration. Patients with resection margins positive for lobular carcinoma in-situ will be eligible.
2. Patients must be registered with 84 days from the final surgical procedure required to adequately treat the primary tumor and/or axilla.
3. Patients must not have received prior cytotoxic chemotherapy for breast cancer.
4. Patients must not have received prior radiation therapy for current malignancy.
5. Patients with the clinical diagnosis of congestive heart failure or angina pectoris are not eligible.
6. Patients must have normal liver function.

Patients must be experiencing therapeutic benefits while receiving treatment with lapatinib through participation in a Phase I study of lapatinib.Patients may be male or female.

1. Patients must have primary adenocarcinoma of the breast confirmed by histology or cytology.
2. Patients must have locally advanced or metastatic disease not amenable to surgery or radiation therapy with curative intent.
3. Progressive disease following hormonal therapy in appropriate patients (ER-positive and/or indolent disease).
4. Progressive disease following treatment with both an anthracycline and a taxane (as adjuvant therapy or for metastatic disease) or contraindication to such treatment.
5. Patients must have normal kidney, liver and bone marrow function.

1. Patients must have advanced or recurrent solid malignancy confirmed histologically or cytologically for which no effective therapy is available.
2. Patients must have measurable and/or evaluable disease as outlined by RECIST criteria.
3. Patients must not have received any systemic antitumor agents or any investigational agent within 28 days prior to the first dose of test article.
4. Patients must not have had prior exposure to SKI-606 or any other Src-kinase inhibitor.
5. Patients must have normal kidney, liver and bone marrow function.

1. Patients diagnosed with solid tumor cancers.
2. Patients must be receiving neoadjuvant or adjuvant treatment for loco-regional definitive therapy or systemic therapy for metastatic (Stage IV) disease with taxane and/or platinum containing regimens.
3. Patients must have a history of diabetes mellitus (Types I or II).
4. Patients must not have received previous treatment with chemotherapy

1. Patients must have a diagnosis of invasive adenocarcinoma that is HER2-positive.
2. Patients must have undergone either a total mastectomy and an axillary dissection or a lumpectomy and an axillary dissection.
3. Patients must not have metastatic disease.
4. Patients must have a life expectancy of at least 10 years, excluding a diagnosis of cancer.
5. Patients must have normal heart, bone marrow, liver and kidney function.

1. Patients must be premenopausal and must have histologically proven, resected breast cancer that is hormone receptor positive.
2. Tumor must be confined to the breast and axillary nodes without detected metastases elsewhere, with the exception of tumor detected in internal mammary chain nodes by sentinel node procedure.
3. Patients must have had proper surgery for primary breast cancer with no known clinical residual loco-regional disease.
4. Either axillary lymph node dissection or a negative axillary sentinel node biopsy is required.
5. Patients who have had a bilateral oopherectomy or ovarian irradiation or are planning oopherectomy within 5 years are not eligible.

1. Patients must have a diagnosis of invasive adenocarcinoma that is T1-3 by clinical and pathologic evaluation and lymph nodes must be histologically negative by standard H & E staining.
2. Patients must have a life expectancy of at least 10 years, excluding a diagnosis of breast cancer.
3. The interval between the last surgery for breast cancer treatment and randomization must be no more than 84 days.
4. Patients must have no evidence of metastatic disease.
5. Patients must have normal heart, bone marrow, kidney and liver function.

1. Patients must have histologically confirmed invasive carcinoma of the female breast, with negative axillary lymph nodes.
2. Patients must have undergone either modified radical mastectomy or lumpectomy, within 84 days of registration.
3. Patients must not have received previous chemotherapy or hormonal therapy for this malignancy. Patients may have received up to 4 weeks of tamoxifen or another selective estrogen receptor modulator for prevention or for other indications. 
4. Patients with locally advanced, metastatic or inflammatory breast cancer are not eligible.
5. Patients must have normal bone marrow, liver and kidney function.

1. Patients must be treated for recurrent ovarian cancer, metastatic breast cancer or advanced endometrial cancer.
2. Patients must be initiating Doxil chemotherapy. Patients may receive concurrent chemotherapy so long as the additional chemotherapeutic agent does not cause PPE/HFS.
3. Any hormonal therapy directed at the malignant tumor, must be discontinued at least one week prior to registration. Any other prior therapy directed at the malignant tumor, including radiotherapy, biological and immunologic agents, must be discontinued at least 3 weeks prior to registration.
4. Patients who have had prior therapy with Doxil are not eligible.
   5. Patients must have normal bone marrow, liver, kidney and heart function.

1. Patients must have completely resected and histologically confirmed invasive breast cancer which was pT1, pT2 or pT3, pNx, pN0, or pN1, M0 (AJCC).
2. The primary tumor must be receptor-positive i.e., ER and/or PgR positive.
3. Patients must have postmenopausal status prior to chemotherapy.
4. Patients with only synchronous bilateral breast cancer are eligible. Either or both tumors need to have receptor positive markers. Once could be negative.
5. Patients must have had a bilateral mammogram within 10 months prior to randomization.
6. Patients must have no radiologic evidence of metastases.
7. Patients must be randomized a minimum of 3 weeks and a maximum of 3 months after completion of chemotherapy.
8. Patients must have adequate bone marrow, kidney and liver function.

1. Men or women with Stage IIA-IIIA invasive breast cancer and 10 or more axillary lymph nodes; must have undergone lumpectomy or mastectomy with axillary lymph node dissection.
2. Margins of resection must be free of disease and protocol treatment must begin within 8 weeks of surgery.
3. ECOG Performance Status of 0 or 1
4. No evidence of systemic metastatic disease after staging evaluation
5. No severe concurrent medical or psychiatric illness
6. Adequate renal, hepatic, and hematologic function as determined by blood levels
7. Patients with a known sensitivity to E. coli are not eligible.